We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Outlook Therapeutics Inc (OTLK) USD0.01

Sell:$1.18 Buy:$1.21 Change: $0.03 (2.46%)
Market closed |  Prices as at close on 9 August 2022 | Switch to live prices |
Change: $0.03 (2.46%)
Market closed |  Prices as at close on 9 August 2022 | Switch to live prices |
Change: $0.03 (2.46%)
Market closed |  Prices as at close on 9 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Outlook Therapeutics, Inc. (Outlook) is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Contact details

485 Route 1 South, Building F, Suite 320
United States
+1 (609) 6193990

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$275.65 million
Shares in issue:
225.94 million
United States
US dollar

Key personnel

  • Ralph Thurman
    Independent Executive Chairman of the Board
  • C. Russell Trenary
    President, Chief Executive Officer, Director
  • Lawrence Kenyon
    Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
  • Terry Dagnon
    Chief Operations Officer
  • Alicia Tozier
    Senior Vice President - Marketing & Market Access
  • Joel Prieve
    Senior Vice President - Commercial Operations
  • Jeff Evanson
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.